Intellia Therapeutics (NTLA) Asset Utilization Ratio (2016 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Asset Utilization Ratio of 0.08 for Q1 2026, up 97.25% year-over-year from 0.04 in Q1 2025, and up 7.82% quarter-over-quarter from 0.08 in Q4 2025.
Intellia Therapeutics (NTLA) Asset Utilization Ratio (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Asset Utilization Ratio for 11 consecutive years, with 0.08 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 97.25% year-over-year to 0.08; the TTM figure through Mar 2026 stood at 0.08 (up 97.25% YoY), while the FY2025 annual figure was 0.07, up 43.31% from the prior year.
- Asset Utilization Ratio improved to 0.08 in Q1 2026 per NTLA's latest filing, from 0.08 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.08 in Q1 2026 and bottomed at 0.03 in Q4 2023.
- Historically, Asset Utilization Ratio has averaged 0.05 across 5 years, with a median of 0.04 in 2023.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio slumped 59.0% — and 2026, when it surged 97.25%.
- Intellia Therapeutics' Asset Utilization Ratio stood at 0.04 in 2022, then decreased by 28.75% to 0.03 in 2023, then soared by 71.69% to 0.05 in 2024, then surged by 56.41% to 0.08 in 2025, then climbed by 7.82% to 0.08 in 2026.
- Business Quant data shows NTLA's Asset Utilization Ratio at 0.08 in Q1 2026, 0.08 in Q4 2025, and 0.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.07 |
| Mar 31, 2026 | 0.08 |
| Dec 31, 2025 | 0.08 |
| Sep 30, 2025 | 0.06 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.04 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.04 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.04 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | 0.03 |
| Sep 30, 2021 | 0.03 |